IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells

BACKGROUND: ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions. Autoantibodies can be related with a dysfunctional immune system, although their associa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Ugolini, Alessio, Zizzari, Ilaria Grazia, Ceccarelli, Fulvia, Botticelli, Andrea, Colasanti, Tania, Strigari, Lidia, Rughetti, Aurelia, Rahimi, Hassan, Conti, Fabrizio, Valesini, Guido, Marchetti, Paolo, Nuti, Marianna
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7658668/
https://ncbi.nlm.nih.gov/pubmed/33166793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados